ANI to Acquire Novitium Pharma, Strengthening R&D, Generics, CDMO

 

• Creates Sustainable Generics Growth Engine with Approximately 25+ Launches Expected in 2021 and 2022
• Expands Brand Portfolio with Addition of 505(b)(2) Pipeline and Enhances Scale of CDMO Business
• Purchase Price of $163.5 Million, including $89.5 Million in Cash and $74 Million in Equity, plus Two Potential Future Earnouts of Up to $46.5 Million
• Expected to be Accretive to Adjusted non-GAAP Earnings per Share within First 12 Months
• Strengthens Capital Structure with New Senior Credit Facilities of $340 Million (Replacing the Company’s Existing Term Loan A) Committed by Truist Securities and $25 Million PIPE by Ampersand Capital Partners

https://www.biospace.com/article/releases/ani-pharmaceuticals-to-acquire-novitium-pharma-strengthening-r-and-amp-d-engine-and-expanding-generics-and-cdmo-business/